1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Mesoblast Limited

Mesoblast Limited

MEOBF
Mesoblast LimitedUS flagOther OTC
1.70
USD
+0.15
- -
2.20BMarket Cap
Mesoblast Limited
MEOBF
(Other OTC)

Recent

price

1.70

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.01
0.52
0.13
0.09
0.07
0.06
0.11
- -
0.03
0.03
0.06
0.01
0.01
0.01
0.01
0.01
- -
Revenue per Share
-0.1
0.39
-0.24
-0.2
-0.22
-0.28
-0.01
-0.18
-0.07
-0.17
-0.14
-0.15
-0.13
-0.11
-0.09
-0.08
- -
Basic EPS, GAAP
-0.07
0.47
-0.25
-0.18
-0.23
-0.36
-0.23
-0.23
-0.15
-0.11
-0.11
-0.16
-0.1
-0.08
-0.05
-0.04
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.37
0.15
1.49
1.77
1.46
1.3
1.31
1.15
1.04
0.84
0.9
0.81
0.62
0.55
0.41
0.41
- -
Book Value per Share
0.25
0.18
-0.06
0.26
-0.34
-0.53
-0.16
-0.17
-0.08
-0.2
-0.06
- -
-0.12
-0.1
-0.1
0.02
- -
Tangible Book Value per Share
150
231
301
315
340
342
384
421
491
522
558
638
683
778
987
1,208
- -
Basic Weighted Avg Shares
1
121
38
29
23
20
41
2
17
17
32
7
10
8
6
17
- -
Sales/Revenue/Turnover
-1,357.91
80.36
-127.7
-205.64
-287.55
-462.46
-137.37
-4,655.86
-443.1
-480.86
-238.55
-1,447.44
-794.31
-923.73
-982.24
-363.08
- -
Operating Margin (%)
- -
- -
- -
1
1
2
2
3
3
2
4
4
4
4
5
6
- -
Depreciation Expense
-15
91
-71
-62
-76
-96
-4
-77
-35
-90
-78
-99
-91
-82
-88
-102
- -
Net Income, GAAP
- -
1.77
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-1,932.36
74.96
-186.46
-214.21
-322.93
-487.04
-9.95
-3,951.39
-207.89
-537.01
-246.54
-1,329.18
-894.59
-1,091.71
-1,490.27
-593.92
- -
Profit Margin (%)
32
235
172
281
161
74
59
27
77
18
46
54
18
40
13
102
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
59
67
63
50
99
106
102
71
- -
LT Debt
38
516
479
630
572
468
528
517
546
481
549
581
497
502
480
597
- -
Total Equity
- -
34.46
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
-877.9
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-29.41
-12.27
-14.32
-20.4
-0.87
-15.55
-7.09
-18.91
-16.53
-19.41
-19.39
-19.16
-21.18
-22.7
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
- -
69
- -
LT Borrowings
- -
60
- -
LT Finance Leases
- -
6
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
1,289
- -
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
- -
202
- -
Cash, Cash Equivalents & STI
- -
130
- -
Accounts Receivable, Net
- -
43
- -
Inventories
- -
22
- -
Total Current Liabilities
- -
128
- -
Payables & Accruals
- -
34
- -
ST Debt
- -
69
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.1%
2.48%
24.38%
Free Cash Flow
-4.79%
3.22%
3.88%
Net Income, GAAP
178.52%
6.48%
16.13%
Sales/Revenue/Turnover
97.97%
20.88%
191.39%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
6
2025
- -
- -
- -
- -
17
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.09
2025
- -
- -
- -
- -
-0.08
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Midatech Pharma plc (MTP)
Genus plc (GNS.L)
Pherecydes Pharma S.A. (ALPHE.PA)
Biosergen AB (BIOSGN.ST)
eXoZymes, Inc. (EXOZ)
ContraFect Corp. (CFRXQ)
Business
Mesoblast Limited Mesoblast Limited (ASX:MSB; Nasdaq:MESO) is a biopharmaceutical company that develops and commercializes allogeneic cellular medicines derived from proprietary mesenchymal lineage cells for the treatment of serious inflammatory diseases; its lead product, RYONCIL (remestemcel-L), targets steroid-refractory acute graft versus host disease (SR-aGVHD) in pediatric patients; additional Phase 3 candidates include remestemcel-L for adult SR-aGVHD and biologic-resistant inflammatory bowel disease, REVASCOR (rexlemestrocel-L) for advanced chronic heart failure, and MPC-06-ID for chronic low back pain due to degenerative disc disease. Founded in 2004 and headquartered in Melbourne, Australia, with operations in the United States, Singapore, Japan, Europe, and China, the company maintains industrial-scale manufacturing processes for off-the-shelf, cryopreserved cell therapies supported by a patent portfolio exceeding 1,000 patents extending to 2044. Recent developments include FDA approval of RYONCIL in December 2024 as the first mesenchymal stromal cell therapy for pediatric SR-aGVHD, its commercial launch and availability at leading U.S. pediatric transplant centers, strategic alliances with Tasly Pharmaceutical Group, JCR Pharmaceuticals, and Grünenthal for development and commercialization, and projected gross revenue exceeding US$30 million for the quarter ending December 31, 2025, reflecting over 37% sequential growth driven by expanding RYONCIL adoption.

Company News

APIChatGPT

  • defenseworld.net

    Short Interest in Mesoblast Limited (OTCMKTS:MEOBF) Decreases By 14.2%